This post is from a suggested group
Shifting Therapeutic Landscape: The Growing Influence of Biologics in the Sarcoidosis Drug Market
Description
The Sarcoidosis Drug Market is undergoing a significant transformation, driven by the persistent challenge of chronic disease management and the recognized limitations of conventional therapies. Sarcoidosis, an inflammatory disease resulting in granuloma formation, most commonly affects the lungs (pulmonary sarcoidosis) but can impact any organ. The market is currently dominated by Corticosteroids (e.g., oral prednisone), which are the established first-line treatment due to their effectiveness in controlling inflammation. However, this dominance is eroding due to the high incidence of long-term toxicity associated with prolonged steroid use, including weight gain, osteoporosis, and diabetes.
The increasing demand for steroid-sparing regimens is rapidly expanding the market for alternative drug classes. Immunosuppressants, such as methotrexate and azathioprine, form the core second-line treatment, aiming to control the disease while minimizing corticosteroid dependence. However, the fastest-growing and most promising segment involves Biologics,…